CDKN2A and cancer: Early experiments on lifespan extension via increased telomerase reverse transcriptase (TERT) activity involved mice with cancer resistant genetic backgrounds with enhanced expression of the tumor suppressors p53, p16, and p19ARF to counter the supposed oncogenic effect of telomerase [13].